Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
AstraZeneca
BeOne Medicines
BeOne Medicines
Incyte Corporation
Mersana Therapeutics
Cellectar Biosciences, Inc.
Eli Lilly and Company
Iambic Therapeutics, Inc
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
ExpreS2ion Biotechnologies
Boundless Bio, Inc.
Regor Pharmaceuticals Inc.
Halda Therapeutics OpCo, Inc.
Novartis
Fate Therapeutics
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Pfizer
Genentech, Inc.
Regor Pharmaceuticals Inc.
Eli Lilly and Company
Cogent Biosciences, Inc.
EMD Serono
GlaxoSmithKline
SystImmune Inc.
Orano Med LLC
Atavistik Bio, Inc
BioNTech SE
Novartis
Pfizer
NiKang Therapeutics, Inc.
Genentech, Inc.
Eisai Inc.
TerSera Therapeutics LLC
Alterome Therapeutics, Inc.
BeOne Medicines
Rovi Pharmaceuticals Laboratories
ViroMissile, Inc.
Eisai Inc.
Replimune Inc.
Kind Pharmaceuticals LLC
OncoTherapy Science, Inc.
Myeloid Therapeutics
Tizona Therapeutics, Inc
SURGE Therapeutics